Natera (NTRA) said Tuesday that its Signatera test for patients diagnosed with lung cancer has met coverage requirements for the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program.
The company said the coverage is intended for patients with non-small cell lung cancer, specifically patients with stage 1 through stage 3 NSCLC with resectable or unresectable disease.
Natera said the new coverage expands its preexisting Medicare coverage of Signatera for monitoring immunotherapy in adjuvant and metastatic settings.
Price: 154.55, Change: -3.83, Percent Change: -2.42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.